HSTCLHepatosplenic T-Cell Lymphoma
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
This unique surface [CD3.sup.-] HSTCL case highlights the significant but often underappreciated overlap in clinical, morphologic, and immunophenotype findings between HSTCL and NK-cell neoplasms, in particular ANKL.
Morphologically, HSTCL is characterized by homogeneous, mature, medium-sized postthymic T-lymphocytes infiltrating into the sinusoids and sinuses of the liver and spleen, respectively.
However, these characteristics were present in the circulating neoplastic cells of our patient with HSTCL. The morphologic impression of the neoplastic cells seen in the peripheral blood of our case initially favored ANKL over HSTCL.
Immunophenotypically, the tumor cells of HSTCL usually express surface CD3, CD2, and CD7 and lack CD4, CD5, and CD8, with 15% of cases being [CD4.sup.-]/[CD8.sup.+].
With the exception of lacking surface CD3 expression, ANKL cases can show an immunophenotype that is almost identical to that of HSTCL. The ANKL cases usually are [CD2.sup.+] cytoplasmic CD3[[epsilon].sup.+] [CD56.sup.+] [TIA-1.sup.+], [CD4.sup.-], [CD5.sup.-], and [CD8.sup.-].7 Similar to HSTCL, CD11b and CD16 show variable expression, while CD57 is usually negative.
Our case demonstrated significant morphologic and immunologic overlap between HSTCL and NK-cell neoplasms.
Among these 25 cases were 10 reports of HSTCL. There are no known cases of HSTCL in patients treated with a TNF antagonist without a history of previous or concomitant thiopurine treatment, according to the FDA.